RxDoctor Payments Data

Leslie Cordial, APRN

Family · Clay City, KYNPI 1841854924

Payments from drug & device makers

$920in general payments, 2019–2025

Across 56 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$332
  • GSK$220
  • Pfizer$63
  • Mylan Specialty L.p.$43
  • Otsuka America Pharmaceutical, Inc.$36
  • Neurelis, Inc.$35
  • plus $191 from 8 others

What the payments were for

  • Food & beverage$920100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$920 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$511
Medicare patients
21
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$46,943
OzempicSemaglutide43$39,681
VraylarCariprazine Hcl19$31,984
FarxigaDapagliflozin Propanediol30$28,823
MounjaroTirzepatide23$27,059
UbrelvyUbrogepant18$20,954
JanuviaSitagliptin Phosphate21$18,612
EliquisApixaban17$17,879
LinzessLinaclotide20$11,587
TrulancePlecanatide18$9,772
JanumetSitagliptin Phos/Metformin Hcl12$6,663
Albuterol Sulfate HfaAlbuterol Sulfate85$2,871
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,131
Gabapentin177$1,842
Duloxetine Hcl45$1,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Ubrelvy, Linzess$332$64,52557 claims
GSKTrelegy Ellipta$220$46,94349 claims
Novo NordiskOzempic$23$39,68143 claims
AstraZenecaFarxiga$19$28,82330 claims
Lilly USA, LLCMounjaro, Olanzapine$19$27,42346 claims
PfizerEliquis$63$17,87917 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$22$9,77218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in Clay City

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →